πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Intellia Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Alector, Inc.

Alector, Inc. logo
Market Cap: Medium
Employees: Low

AL001, AL101, AL002, AL003, AL044

Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegeneration diseases. The company has several products in various stages of clinical trials aimed at treating conditions such as Alzheimer's, Parkinson's, and frontotemporal dementia.

Tags: Alzheimer's, Parkinson's, biopharmaceutical, clinical trials, neurodegeneration, therapies

Symbol: ALEC

Recent Price: $1.72

Industry: Biotechnology

CEO: Dr. Arnon Rosenthal Ph.D.

Sector: Healthcare

Employees: 245

Address: 131 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 415 231 5660

Leadership

  • Arnon Rosenthal, Ph.D., Co-Founder, Chief Executive Officer, and Director
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development
  • Marc Grasso, M.D., Chief Financial Officer
  • Gary Romano, M.D., Ph.D., Chief Medical Officer
  • Danielle Pasqualone, Ph.D., J.D., General Counsel
  • Clare Hunt, M.B.A., Chief People Officer
  • Kristina Cutter, M.P.H., Chief Regulatory, Pharmacovigilance, and Quality Assurance Officer
  • Virginia DeJesus-Rueff, M.B.A., Chief of Staff and Head of Strategy
  • Norah Conway, Senior Vice President, Portfolio and Program Management
  • Neil Berkley, M.S., M.B.A., Chief Business Officer
  • Louis J. Lavigne Jr., M.B.A., Chairperson of the Board
  • Elizabeth Garofalo, M.D., Board Member
  • Paula Hammond, Ph.D., Board Member
  • Richard H. Scheller, Ph.D., Board Member
  • David Wehner, Board Member
  • Kristine Yaffe, M.D., Board Member
  • Errol De Souza, Ph.D., Board Member
  • Mark Altmeyer, M.B.A., Board Member

Last updated: 2024-12-31

BioAtla, Inc.

BioAtla, Inc. logo
Market Cap: Low
Employees: Low

BA3011

Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.

Tags: antibody-based therapeutics, biopharmaceutical, cancer, clinical stage, solid tumor

Symbol: BCAB

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Jay M. Short Ph.D.

Sector: Healthcare

Employees: 65

Address: 11085 Torreyana Road, San Diego, CA 92121

Phone: 858 558 0708

Last updated: 2024-12-31

Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

AT-1501

Eledon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing medicines for autoimmune diseases, amyotrophic lateral sclerosis (ALS), and organ or cell-based transplants. Its lead product candidate AT-1501 is in Phase 2 clinical trials.

Tags: ALS, autoimmune disease, biopharmaceutical, clinical trials, organ transplant

Symbol: ELDN

Recent Price: $4.14

Industry: Biotechnology

CEO: Dr. David-Alexandre C. Gros M.D., Ph.D.

Sector: Healthcare

Employees: 20

Address: 19900 MacArthur Boulevard, Irvine, CA 92612

Phone: 949 238 8090

Last updated: 2024-12-31

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

TELOMIR-1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.

Tags: TELOMIR-1, inflammatory conditions, pharmaceutical, stem cells, therapeutic treatment

Symbol: TELO

Recent Price: $4.64

Industry: Biotechnology

CEO: Mr. Erez Aminov

Sector: Healthcare

Employees: 1

Address: 855 N Wolfe Street, Baltimore, null 21205

Phone: (737)-289-0835

Last updated: 2024-12-31

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. logo
Market Cap: Medium
Employees: Lowest

TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101

Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.

Tags: CNS, biotechnology, gene therapy, healthcare, monogenic diseases

Symbol: TSHA

Recent Price: $1.73

Industry: Biotechnology

CEO: Mr. Sean P. Nolan

Sector: Healthcare

Employees: 52

Address: 3000 Pegasus Park Drive, Dallas, TX 75247

Phone: 214 612 0000

Last updated: 2024-12-31

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALRN-6924

Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.

Tags: ALRN-6924, cancer therapies, chemoprotection, clinical stage, clinical trials, oncology

Symbol: ALRN

Recent Price: $2.32

Industry: Biotechnology

CEO: Dr. James Brian Windsor Ph.D.

Sector: Healthcare

Employees: 15

Address: 285 Summer Street, Boston, MA 02210

Phone: 617 995 0900

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Astria Therapeutics, Inc.

Astria Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

STAR-0215

Astria Therapeutics, Inc., is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases in the United States. Its lead product candidate, STAR-0215, is targeting hereditary angioedema.

Tags: allergic diseases, biopharmaceutical, hereditary angioedema, immunological diseases, rare diseases

Symbol: ATXS

Recent Price: $8.88

Industry: Biotechnology

CEO: Ms. Jill C. Milne Ph.D.

Sector: Healthcare

Employees: 59

Address: 100 High Street, Boston, MA 02110

Phone: 617 349 1971

Last updated: 2024-12-31

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

INT230-6

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of cancer drugs for treating solid tumors. Their lead product, INT230-6, is undergoing Phase 2 trials for various cancers and is being tested in collaborations with major pharmaceutical companies.

Tags: biotechnology, cancer treatment, clinical trials, collaboration, solid tumors

Symbol: INTS

Recent Price: $1.82

Industry: Biotechnology

CEO: Mr. Lewis H. Bender M.A., M.B.A., M.S.

Sector: Healthcare

Employees: 5

Address: 61 Wilton Road, Westport, CT 06880

Phone: 203 221 7381

Leadership

  • Lewis H. Bender, M.S., M.A., M.B.A., Founder and CEO
  • Joseph Talamo, CPA, Chief Financial Officer
  • James M. Ahlers, Executive Vice President
  • Brian Schwartz, MD, Executive VP, Clinical Development
  • John Wesolowski, CPA, MBA, Principal Accounting Officer and Controller
  • Kimberly A. Guedes, RN, MBA, Vice President of Clinical Operations
  • Doranne Frano, Regulatory Affairs and Quality Control
  • Daniel J. Donovan, Board Member and Chief Executive Officer
  • Tom Dubin, Board Member
  • Mark A. Goldberg, MD, Board Member
  • Emer Leahy, Ph.D., Board Member

Last updated: 2024-12-31

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. logo
Market Cap: Highest
Employees: Medium

CAPLYTA

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing novel drugs for the treatment of neuropsychiatric and neurologic diseases targeting intracellular signaling in the central nervous system. Key products include CAPLYTA for schizophrenia and ongoing developments in treatments for bipolar depression, autism spectrum disorder, and more.

Tags: biopharmaceutical, bipolar depression, central nervous system, drug development, neurologic diseases, neuropsychiatric, schizophrenia

Symbol: ITCI

Recent Price: $83.48

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. Sharon Mates Ph.D.

Sector: Healthcare

Employees: 610

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 440 9333

Leadership

  • Sharon Mates, Ph.D., Chairman, Founder & Chief Executive Officer
  • Michael I. Halstead, J.D., President
  • Mark Neumann, Executive Vice President, Chief Commercial Officer
  • Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer
  • Sanjeev Narula, Executive Vice President, Chief Financial Officer
  • John A. Bardi, Senior Vice President, Market Access, Policy and Government Affairs
  • Robert E. Davis, Ph.D., Senior Vice President, Chief Scientific Officer
  • Karen Sheehy, Esq., Senior Vice President and Chief Compliance Officer
  • Michael Olchaskey, Pharm.D., Senior Vice President, Head of Regulatory Affairs
  • Juan Sanchez, M.D., Vice President of Corporate Communications and Investor Relations
  • Willie R. Earley, M.D., Senior Vice President, Head of Clinical Development
  • Joel S. Marcus, J.D., CPA, Executive Chairman & Founder
  • Rory B. Riggs, MBA, Co-Founder and Director
  • E. Rene Salas, CPA, Former Senior Client Partner at Ernst & Young, LLP; Former CFO, Wellstat, LLC
  • Robert L. Van Nostrand, Chairman, Metabolix; Board Member, Achillion Pharmaceuticals; Former CFO, OSI Pharmaceuticals

Last updated: 2024-12-31

LogicBio Therapeutics, Inc.

LogicBio Therapeutics, Inc. logo
Market Cap: Low
Employees: Medium

LB-001

Logic Bio Therapeutics, Inc. is a genetic medicine company focused on genome editing and gene therapy treatments using its Gene Ride and s AAVy platforms. Its lead product candidate, LB-001, is in clinical trials for methylmalonic acidemia.

Tags: Gene Ride, LB-001, gene therapy, genetic medicine, genome editing, methylmalonic acidemia, s AAVy

Symbol: LOGC

Recent Price: $7.08

Industry: Biotechnology

CEO: Mr. Rishi Bajaj

Sector: Healthcare

Employees: 452

Address: 65 Hayden Ave, 2Nd Floor, Lexington, MASSACHUSETTS 02421

Phone: 16172450399

Last updated: 2024-12-31

Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

HONEDRA, XOWNA, CLBS201

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cellular therapies to reverse disease and regenerate damaged tissue.

Tags: biopharmaceutical, cellular therapies, chronic kidney disease, clinical-stage, coronary microvascular dysfunction, critical limb ischemia

Symbol: LSTA

Recent Price: $2.94

Industry: Biotechnology

CEO: Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.

Sector: Healthcare

Employees: 25

Address: 110 Allen Road, Basking Ridge, NJ 07920

Phone: 908 842 0100

Leadership

  • David J. Mazzo, PhD, President and Chief Executive Officer
  • Kristen K. Buck, MD, Executive Vice President of R&D and Chief Medical Officer
  • Gregory S. Berkin, Chief Information Officer and Data Protection Officer
  • Gail Holler, Vice President, Human Resources
  • John D. Menditto, Vice President, Investor Relations and Corporate Communications
  • James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer
  • William K. Sietsema, PhD, Vice President, Global Regulatory Affairs
  • Ryan Quick, Vice President, Chemistry, Manufacturing and Controls
  • Tariq Imam, Vice President, Business Development and Operations and Corporate Counsel
  • Gregory B. Brown, MD, Chairman
  • Steven M. Klosk, Director
  • Cynthia L. Flowers, Director
  • Mohammad Azab, MD, MSc, MBA, Director
  • Heidi Henson, Director

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

NTLA-2001, NTLA-2002, NTLA-5001

Intellia Therapeutics, Inc. is a genome editing company specializing in developing therapeutics, with a focus on in vivo and ex vivo programs, including treatments for transthyretin amyloidosis, hereditary angioedema, and acute myeloid leukemia. The company also develops engineered cell therapies and offers CRISPR/Cas9 tools.

Tags: CRISPR, autoimmune disorders, ex vivo, genome editing, in vivo, oncology, therapeutics

Symbol: NTLA

Recent Price: $11.41

Industry: Biotechnology

CEO: Dr. John M. Leonard M.D.

Sector: Healthcare

Employees: 526

Address: 40 Erie Street, Cambridge, MA 02139

Phone: 857 285 6200

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

Denali Therapeutics Inc.

Denali Therapeutics Inc. logo
Market Cap: High
Employees: Medium

BIIB122/DNL151

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutic candidates for neurodegenerative diseases. Its pipeline includes treatments for Parkinson's disease, hunter syndrome, ALS, multiple sclerosis, and Alzheimer's disease. It collaborates with companies such as Takeda Pharmaceutical Company and Genentech, Inc.

Tags: ALS, Alzheimer's disease, Parkinson's disease, biopharmaceutical, hunter syndrome, multiple sclerosis, neurodegenerative diseases

Symbol: DNLI

Recent Price: $20.24

Industry: Biotechnology

CEO: Dr. Ryan J. Watts Ph.D.

Sector: Healthcare

Employees: 364

Address: 161 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 866 8548

Last updated: 2024-12-31

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Medium

RNA-targeted therapeutics

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.

Tags: ALS, Biotechnology, Pharmaceuticals, RNA therapeutics, SPINRAZA, TEGSEDI, TTR amyloidosis, WAYLIVRA

Symbol: IONS

Recent Price: $34.92

Industry: Biotechnology

CEO: Dr. Brett P. Monia Ph.D.

Sector: Healthcare

Employees: 927

Address: 2855 Gazelle Court, Carlsbad, CA 92010

Phone: 760 931 9200

Last updated: 2024-12-31

Lantheus Holdings, Inc.

Lantheus Holdings, Inc. logo
Market Cap: Highest
Employees: Medium

DEFINITY, Techne Lite, Xenon-133, Neurolite, Cardiolite, Thallium-201, Gallium-67, AZEDRA, Automated Bone Scan Index, Cobalt (Co 57), RELISTOR

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

Tags: cardiovascular, diagnostic products, healthcare, oncology, radiotherapy, therapeutic products

Symbol: LNTH

Recent Price: $89.13

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Brian A. Markison

Sector: Healthcare

Employees: 834

Address: 331 Treble Cove Road, North Billerica, MA 01862

Phone: 978 671 8001

Leadership

  • Brian Markison, Chief Executive Officer
  • Paul Blanchfield, President
  • Jeff Humphrey, MD, Chief Medical Officer
  • Robert J. Marshall Jr., Chief Financial Officer
  • Amanda Morgan, Chief Commercial Officer
  • Daniel Niedzwiecki, Chief Administrative Officer, General Counsel and Corporate Secretary
  • Jean-Claude Provost, MD, Chief Science Officer
  • Jamie Spaeth, Chief People Officer
  • Cheryl Ball, Senior Vice President, Strategy and Enterprise Planning
  • Dorothy Barr, Senior Vice President, Manufacturing and Technical Operations
  • Kim Brown, Chief Accounting Officer
  • Lee Anne Howe, Chief Information Officer
  • Linda Lennox, Chief of Staff & Vice President, Corporate Communications
  • Joann Nestor, Senior Vice President, Legal Affairs
  • Andrea Sabens, Vice President, Business Optimization
  • Carol Walker, Senior Vice President, Quality
  • Mary Anne Heino, Chairperson of the Board
  • Minnie Baylor-Henry, Director
  • GΓ©rard Ber, PhD, Director
  • Julie Eastland, Director
  • Samuel Leno, Director
  • Heinz MΓ€usli, Director
  • Julie McHugh, Director
  • Gary J. Pruden, Director
  • James H. Thrall, MD, Director

Last updated: 2024-12-31